Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

CBMG Says Bi-Specific CAR-T Effective in Non-Hodgkin Lymphoma Trial

publication date: Jun 11, 2021

CBMG Holdings, a US-China immunotherapy company, said its novel bi-specific CAR-T candidate was effective in an early-stage China lymphoma trial. C-CAR039, a second-gen 4-1BB CD19/CD20 bi-specific, produced an overall 92% overall response rate in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). The complete response rate was 85%. In addition, the US FDA granted orphan drug designation to C-CAR039 in patients with follicular lymphoma. CBMG was known as Cellular Biomedicine before it was taken private in a management-led buyout. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital